Not yet recruitingPhase 1NCT07460765

Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

Studying Squamous cell carcinoma of the oral cavity

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Vanderbilt-Ingram Cancer Center
Principal Investigator
Eben Rosenthal, MD, MD
Vanderbilt University/Ingram Cancer Center
Intervention
Nivo800(drug)
Enrollment
40 target
Eligibility
18 years · All sexes
Timeline
20262031

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07460765 on ClinicalTrials.gov

Other trials for Squamous cell carcinoma of the oral cavity

Additional recruiting or active studies for the same condition.

See all trials for Squamous cell carcinoma of the oral cavity

← Back to all trials